Sepsis Diagnostics Market

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical journals, clinical microbiology publications, and authoritative health surveillance organizations. Key sources included the US Food & Drug Administration (FDA), Centers for Disease Control and Prevention (CDC) National Center for Emerging and Zoonotic Infectious Diseases, European Centre for Disease Prevention and Control (ECDC), World Health Organization (WHO) Global Sepsis Alliance, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) ClinicalTrials.gov, Clinical and Laboratory Standards Institute (CLSI), Association for Diagnostics & Laboratory Medicine (ADLM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Society of Critical Care Medicine (SCCM), American Society for Microbiology (ASM), PubMed/MEDLINE infectious disease databases, HCUP National Inpatient Sample (NIS), and national health surveillance reports from key markets.

These sources were employed to gather data on sepsis incidence and mortality, in-vitro diagnostic (IVD) regulatory approval data, clinical validation studies for procalcitonin and lactate biomarkers, antimicrobial resistance patterns, laboratory testing volumes, and competitive landscape analysis for molecular diagnostic platforms, immunoassay analyzers, blood culture systems, and point-of-care testing devices.

Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. The supply-side sources consisted of CEOs, VPs of R&D, regulatory affairs directors, and commercial leaders from in-vitro diagnostic manufacturers, biotechnology companies, and laboratory equipment OEMs. Chief microbiologists, critical care specialists, infectious disease physicians, laboratory directors, and procurement managers from tertiary care hospitals, clinical reference laboratories, academic medical centers, and blood culture facilities constituted demand-side sources. Market segmentation was validated across technology platforms, product development pipelines and 510(k)/CE-mark approval timelines were confirmed, and clinical adoption patterns for rapid sepsis testing, laboratory automation trends, reimbursement coding (CPT/DRG) dynamics, and antimicrobial stewardship program integration were gathered through primary research analysis.

Primary Respondent Breakdown:

By Designation: C-level Primaries (32%), Director Level (31%), Others (37%)

By Region: North America (38%), Europe (29%), Asia-Pacific (25%), Rest of World (8%)

Revenue mapping and testing volume analysis were employed to determine the global market valuation. The methodology comprised the following:

The identification of over 50 main diagnostic manufacturers in North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa

Product mapping across molecular diagnostics (PCR, NGS, syndromic panels), immunoassays (chemiluminescence, ELISA), blood culture systems, and biomarker testing platforms (procalcitonin, C-reactive protein, lactate)

Analysis of annual revenues that are specific to the sepsis diagnostic portfolios and infectious disease testing segments, as reported and modeled

Manufacturers that account for 75-80% of the global market share in 2024 are included in the coverage.

Extrapolation is employed to derive segment-specific valuations for assays, instruments, software, and reagents across hospital, laboratory, and research end-use settings by utilizing bottom-up (test volume × ASP by country/region) and top-down (manufacturer revenue validation) approaches.